Previous studies on TRPV1-targeted therapy have focused mostly on relieving discomfort, such as pain and itching caused by the disease (142, 143), and with increasing research, TRPV1 has been recognized as a potential target with preventive effects against obesity (25). Here, TRPV1 is linked to obesity due to melanocortin 4 receptor deficiency.